FY2020 EPS Estimates for Heron Therapeutics, Inc. (HRTX) Decreased by Analyst

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Analysts at Oppenheimer Holdings dropped their FY2020 earnings per share estimates for Heron Therapeutics in a report released on Friday. Oppenheimer Holdings analyst D. Archila now anticipates that the biotechnology company will post earnings per share of $1.45 for the year, down from their prior estimate of $1.46. Oppenheimer Holdings currently has a “Buy” rating and a $27.00 target price on the stock. Oppenheimer Holdings also issued estimates for Heron Therapeutics’ FY2021 earnings at $3.29 EPS.

HRTX has been the subject of several other reports. Mizuho reissued a “buy” rating and set a $28.00 price target on shares of Heron Therapeutics in a report on Tuesday, November 7th. Cantor Fitzgerald set a $31.00 price target on shares of Heron Therapeutics and gave the stock a “buy” rating in a report on Friday, October 20th. Cowen and Company reissued a “buy” rating and set a $40.00 price target on shares of Heron Therapeutics in a report on Monday, November 6th. BidaskClub raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Finally, Aegis reissued a “buy” rating and set a $33.00 price target on shares of Heron Therapeutics in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $28.36.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.themarketsdaily.com/2017/11/14/fy2020-eps-estimates-for-heron-therapeutics-inc-hrtx-decreased-by-analyst.html.

Heron Therapeutics (NASDAQ:HRTX) traded down $0.48 during midday trading on Monday, reaching $15.33. 734,572 shares of the company traded hands, compared to its average volume of 818,124. Heron Therapeutics has a 52-week low of $12.21 and a 52-week high of $20.85. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.10. The firm had revenue of $8.57 million during the quarter, compared to analysts’ expectations of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%.

A number of institutional investors and hedge funds have recently modified their holdings of HRTX. Janus Henderson Group PLC acquired a new position in Heron Therapeutics during the second quarter worth about $78,134,000. Vanguard Group Inc. grew its position in Heron Therapeutics by 40.2% during the first quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock worth $28,127,000 after buying an additional 537,563 shares during the period. State Street Corp grew its position in Heron Therapeutics by 30.7% during the first quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock worth $26,822,000 after buying an additional 420,113 shares during the period. Chartwell Investment Partners LLC acquired a new stake in shares of Heron Therapeutics in the third quarter valued at approximately $2,340,000. Finally, Credit Suisse AG grew its position in shares of Heron Therapeutics by 329.8% in the first quarter. Credit Suisse AG now owns 144,061 shares of the biotechnology company’s stock valued at $2,161,000 after purchasing an additional 110,539 shares during the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply